利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.028 秒)

    Systems and methods for determining advertising activity
    1.
    发明授权
    Systems and methods for determining advertising activity 有权
    确定广告活动的系统和方法

    公开(公告)号：US08666811B1

    公开(公告)日：2014-03-04

    申请号：US10810725

    申请日：2004-03-29

    申请人： Johnny Chen ,  Darrell Anderson

    发明人： Johnny Chen ,  Darrell Anderson

    IPC分类号： G06Q30/00

    CPC分类号： G06Q30/00 ,  G06Q30/02

    摘要： A system may provide an advertising link in association with a document. The content of the advertising link is unrelated to a content of the document. The system may also determine a rate at which the advertising link is selected and determine whether illegitimate activity occurred based, at least in part, on the determined rate of selection.

    摘要翻译： 系统可以提供与文档相关联的广告链接。 广告链接的内容与文档的内容无关。 系统还可以至少部分地基于确定的选择速率来确定选择广告链接的速率并且确定是否发生非法活动。

    Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens
    4.
    发明申请
    Identification of Unique Binding Interactions Between Certain Antibodies and the Human B7.1 and B7.2 Co-Stimulatory Antigens 有权
    鉴定某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20060275291A1

    公开(公告)日：2006-12-07

    申请号：US11464133

    申请日：2006-08-11

    申请人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 阻断CD28和B7.1（CD80）之间的主要激活信号与这些抗体同时允许CTLA-4和B7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。

    Bridged network topology acquisition
    6.
    发明授权
    Bridged network topology acquisition 有权
    桥接网络拓扑采集

    公开(公告)号：US06614764B1

    公开(公告)日：2003-09-02

    申请号：US09496294

    申请日：2000-02-01

    申请人： Thomas L. Rodeheffer ,  Darrell Anderson ,  Chandramohan A. Thekkath ,  Mark D. Lillibridge

    发明人： Thomas L. Rodeheffer ,  Darrell Anderson ,  Chandramohan A. Thekkath ,  Mark D. Lillibridge

    IPC分类号： H04J1500

    CPC分类号： H04L45/02 ,  H04L12/462 ,  H04L41/12 ,  H04L45/04

    摘要： A bridged network and a method for performing bridged network topology acquisition. The bridged network includes network segments and smart bridges having one or more ports. The network segments are interconnected by the smart bridges via the ports. Each of the smart bridges being configured to perform steps to accomplish the network topology acquisition. The method also performs steps to accomplish the network topology acquisition. The steps include an inventory construction that compiles a list of the ports that are connected to each of the network segments. Among the ports that are connected to any of the network segments the inventory construction respecting each port operates cooperatively so as to cause the list respecting each of the ports to converge rapidly to the state in which all the lists are similar and yielding a uniform segment inventory. The bridged network topology acquisition in each of the smart bridges operates cooperatively with the bridged network topology acquisition in other smart bridges in order to create a total network report from most recent segment inventories. The bridged network topology acquisition includes propagation, collection, and distribution. The bridges network topology acquisition affords better management of network topology changes.

    摘要翻译： 一种桥接网络和一种执行桥接网络拓扑采集的方法。 桥接网络包括具有一个或多个端口的网段和智能桥。 网段通过智能桥经由端口互连。 每个智能桥被配置为执行完成网络拓扑获取的步骤。 该方法还执行完成网络拓扑采集的步骤。 这些步骤包括编制连接到每个网段的端口的列表的库存结构。 在连接到任何网段的端口中，关于每个端口的库存结构协同工作，以使得关于每个端口的列表快速收敛到所有列表相似的状态并产生统一的段库存 。 每个智能桥中的桥接网络拓扑采集与其他智能桥中的桥接网络拓扑采集协同工作，以便创建来自最近段段清单的总网络报告。 桥接网络拓扑采集包括传播，收集和分发。 网桥拓扑收集可以更好地管理网络拓扑变化。

    Systems and methods for transparent configuration authentication of networked devices
    8.
    发明授权
    Systems and methods for transparent configuration authentication of networked devices 有权
    网络设备透明配置认证的系统和方法

    公开(公告)号：US08090951B2

    公开(公告)日：2012-01-03

    申请号：US10627270

    申请日：2003-07-25

    申请人： Úlfar Erlingsson ,  Xavier Boyen ,  Darrell Anderson ,  Wayne Gray

    发明人： Úlfar Erlingsson ,  Xavier Boyen ,  Darrell Anderson ,  Wayne Gray

    IPC分类号： H04L9/32

    CPC分类号： H04L63/12 ,  G06F21/10 ,  G06F21/60 ,  G06Q20/401 ,  H04L63/08 ,  H04L63/123 ,  H04L63/20 ,  H04L2209/608 ,  H04N1/32144 ,  H04N21/8358

    摘要： Methods and systems are disclosed for providing secure transmissions across a network comprising a transmitting device and a receiving device. At the transmitting device, a stream of watermark bits is generated. Next, a plurality of watermarks is generated, each of the plurality of watermarks comprising an index number and a portion of the stream of watermark bits. The watermarks are inserted into each header of a plurality of outgoing packets. At the receiving device, the plurality of outgoing packets are received and it is determined if a received packet is valid based on the watermark in the header of the received packet. The stream of watermark bits may be generated using a stream cipher such as RC4, a block cipher such as 3DES in CBC mode, or other equivalent pseudo-random stream generating techniques.

    摘要翻译： 公开了用于通过包括发射设备和接收设备的网络提供安全传输的方法和系统。 在发送装置，生成水印比特流。 接下来，生成多个水印，多个水印中的每一个包括索引号和水印比特流的一部分。 水印被插入到多个输出分组的每个报头中。 在接收装置中，接收多个输出分组，并且基于接收分组的报头中的水印确定接收到的分组是否有效。 可以使用诸如RC4的流密码，CBC模式中的诸如3DES的块密码或其他等效的伪随机流生成技术来生成水印比特流。

    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS
    10.
    发明申请
    IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效
    识别某些抗体与人B7.1和B7.2共刺激抗原之间的独特结合相互作用

    公开(公告)号：US20070128185A1

    公开(公告)日：2007-06-07

    申请号：US11553302

    申请日：2006-10-26

    申请人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    发明人： Darrell Anderson ,  Nabil Hanna ,  Peter Brams

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C07K16/00 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70532 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-I and b7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

    摘要翻译： 本发明涉及对人B7.1抗原（CD80）特异性并且能够抑制B7.1与CD28受体的结合并且不能抑制B7.1结合的抗体的鉴定 到CTLA-4受体。 尽管存在第二活化配体B7.2（CD86），但是这些抗体16C10和7C10中的两个显着抑制了IL-2的产生。 使用这些抗体阻断CD28和B7.1（CD80）之间的主要激活信号，同时允许CTLA-1和b7.1和/或B7.2的未受损或一致的相互作用代表对阳性共刺激的组合拮抗作用， 对负信号的激动作用。 这些抗体可以用作特异性免疫抑制剂，例如用于治疗自身免疫性疾病和预防器官移植排斥。